Payment overview · 2025
General Payments
$296.66
15 reported records · 7 companies
Healthcare provider profile · identity verified
Anthony Altino, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ORLANDO, FL · NPI 1477539880
Verified facts
What the public records show
CMS Open Payments records show Anthony Altino, M.D. received $296.66 in general payments during 2025 across 15 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $65.52 | 22.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.72 | 18.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.49 | 17.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.95 | 15.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.67 | 12.4% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $29.60 | 10.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.71 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $296.66 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $80.69 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.49 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.49 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.95 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $38.55 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $29.60 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 97 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 31 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 617 | 204 |
| Losartan Potassium | Losartan Potassium | 491 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 453 | 150 |
| Levothyroxine Sodium | Levothyroxine Sodium | 452 | 140 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 437 | 143 |
| Lisinopril | Lisinopril | 407 | 130 |
| Metformin Hcl | Metformin Hcl | 338 | 112 |
| Omeprazole | Omeprazole | 313 | 99 |
| Pravastatin Sodium | Pravastatin Sodium | 303 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 277 | 97 |
| Hydrochlorothiazide | Hydrochlorothiazide | 249 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 239 | 80 |
| Gabapentin | Gabapentin | 236 | 81 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 197 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 179 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 170 | 62 |
| Meloxicam | Meloxicam | 160 | 47 |
| Alprazolam | Alprazolam | 152 | 31 |
| Famotidine | Famotidine | 146 | 54 |
| Carvedilol | Carvedilol | 143 | 53 |
| Hydralazine Hcl | Hydralazine Hcl | 137 | 44 |
| Alendronate Sodium | Alendronate Sodium | 132 | 40 |
| Glimepiride | Glimepiride | 127 | 44 |
| Furosemide | Furosemide | 125 | 47 |
| Baclofen | Baclofen | 120 | 41 |
| Simvastatin | Simvastatin | 108 | 37 |
| Sertraline Hcl | Sertraline Hcl | 107 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 41 |
| Allopurinol | Allopurinol | 105 | 30 |
| Potassium Chloride | Potassium Chloride | 102 | 31 |
| Trazodone Hcl | Trazodone Hcl | 101 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 35 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 98 | 81 |
| Eliquis | Apixaban | 97 | 32 |
| Donepezil Hcl | Donepezil Hcl | 94 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 87 | 25 |
| Metformin Hcl Er | Metformin Hcl | 84 | 29 |
| Temazepam | Temazepam | 81 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 69 | 34 |
| Spironolactone | Spironolactone | 69 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 20 |
| Ibuprofen | Ibuprofen | 68 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 17 |
| Ezetimibe | Ezetimibe | 66 | 24 |
| Azithromycin | Azithromycin | 61 | 52 |
| Januvia | Sitagliptin Phosphate | 61 | 17 |
| Warfarin Sodium | Warfarin Sodium | 61 | 13 |
| Benazepril Hcl | Benazepril Hcl | 57 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 18 |
| Lovastatin | Lovastatin | 56 | 19 |
| Glipizide | Glipizide | 55 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 19 |
| Ondansetron Odt | Ondansetron | 52 | 21 |
| Meclizine Hcl | Meclizine Hcl | 50 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 46 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 14 |
| Atenolol | Atenolol | 41 | 12 |
| Ozempic | Semaglutide | 41 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 40 | 15 |
| Naproxen | Naproxen | 37 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 11 |
| Nifedipine Er | Nifedipine | 32 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 27 |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Jardiance | Empagliflozin | 31 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Primidone | Primidone | 29 | 13 |
| Finasteride | Finasteride | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 22 |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 22 |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 24 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Benzonatate | Benzonatate | 20 | 16 |
| Clonazepam | Clonazepam | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 12 |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Ciclopirox | Ciclopirox | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 16 |
| Pregabalin | Pregabalin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $296.66 · 15 records | Boehringer Ingelheim Pharmaceuticals, Inc. | ABRYSVO, COMIRNATY, CREON, ELIQUIS, JARDIANCE, KISUNLA, LINZESS, Leqembi, Ozempic, PREVNAR 20, REPATHA, Rybelsus | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error